Biomedical engineers at Duke University have significantly enhanced the capabilities of a computational model that simulates the movement of individual cancer cells across long distances within the entire human body.
SpringWorks stalled in pre-launch mode for brand communications after FDA decision delay
SpringWorks Therapeutics was cruising along with its pre-launch marketing plans for its rare desmoid tumor drug candidate nirogacestat. Its FDA decision date was set for
July 7, 2023